KEGG   DRUG: Opinercept
Entry
D11703                      Drug                                   
Name
Opinercept (INN)
Sequence
LPAQVAFTPY APEPGSTCRL REYYDQTAQM CCSKCSPGQH AKVFCTKTSD TVCDSCEDST
YTQLWNWVPE CLSCGSRCSS DQVETQACTR EQNRICTCRP GWYCALSKQE GCRLCAPLRK
CRPGFGVARP GTETSDVVCK PCAPGTFSNT TSSTDICRPH QICNVVAIPG NASMDAVCTS
TSPTRSMAPG AVHLPQPVST RSQHTQPTPE PSTAPSTSFL LPMGPSPPAE GSTGDEPKSC
DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD
GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK
GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK
(Disulfide bridge: 18-31, 32-45, 35-53, 45-387, 56-71, 74-88, 78-96, 98-104, 112-121, 115-139, 142-157, 163-178, 240-240', 246-246', 249-249', 281-341)
  Type
Peptide
Remark
ATC code: L04AB07
Efficacy
Anti-inflammatory, Antirheumatic, TNF-alpha inhibitor
Target
TNF (TNFA, TNFSF2) [HSA:7124] [KO:K03156]
  Pathway
hsa04010  MAPK signaling pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04064  NF-kappa B signaling pathway
hsa04350  TGF-beta signaling pathway
hsa04668  TNF signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AB Tumor necrosis factor alpha (TNF-alpha) inhibitors
     L04AB07 Opinercept
      D11703  Opinercept (INN)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Tumor necrosis factors
    TNF (TNFA, TNFSF2)
     D11703  Opinercept (INN)
Other DBs
CAS: 2055118-96-0
PubChem: 405226569
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system